ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: L21

Striking Discrepancy in the Development of Anti-Drug Antibodies (ADA) in Patients with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) in Response to Infliximab (INF) and Its Biosimilar CT-P13

Jürgen Braun1, Xenofon Baraliakos1, Alex Kudrin2, H. Kim3 and Sang Joon Lee2, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2CELLTRION, Inc., Incheon, South Korea, 3CELLTRION, Inc, Incheon, Republic of Korea, Incheon, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), antibodies and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: ACR Late-breaking Abstract Poster Presentations

Session Type: Late-Breaking Abstracts

Background/Purpose: The differences between RA and AS have been recently highlighted (1). There is evidence that there are major clinical, pathophysiological and genetic differences. In addition, the majority of patients with RA are well known to have autoantibodies such as rheumatoid factor and anti-CCP as well as anti-nuclear antibodies and others, autoantibodies in patients with AS have only recently been described which recognise CD74. Although it is well known that ADA develop in response to anti-TNF agents, especially INF and adalimumab, it is unknown whether the degree of ADA development is different between the two diseases. Here we analysed the difference between RA and AS in mounting ADA by taking advantage of the data obtained in two recent trials performed to show biosimilarity between INF and CT-P13 (2,3). 

Methods: The determination of ADA was performed by an electrochemiluminescent immunoassay using Meso Scale Discovery technology. Tests were performed by ICON Laboratory, Manchester, UK. Because of the bivalent characteristics of the antibody, only the samples containing antibody bound to both the biotinylated anti-CT-P13/INF and the sulfo-tagged anti-CT-P13/INF, generate an electroche-miluminescent signal that is proportional to the amount of antibody present. 

Results: The demographics of both patient groups have been described in detail in the original papers (2,3). Despite of concomitant therapy with methotrexate patients with RA clearly had a higher inciden-ce of ADA to both, INF and CT-P13 in comparison to patients with AS. The observed data are depic-ted in Tables 1a and 1b. There was no difference in ADA development between INF and CT-P13. 

Conclusion:

This is the first study to describe a striking discrepancy in ADA development between patients with RA and AS despite methotrexate therapy in the former. Of course, patients with RA and AS differ in age, gender, genetic background and other factors but the reason for the observed difference is not clear. Further research is necessary to clarify its pathophysiologic basis. There seems to be potential to learn about the nature of the disease and the mechanisms of ADA development.

Category

CT-P13 RA (n=302)

CT-P13 AS (n=128)

p value

screening

3.0 (9/301)

1.6 (2/127)

0.52

Week 14

25.4 (69/272)

9.1 (11/121)

< 0.001

Week 30

48.4 (122/252)

27.4 (32/117)

< 0.001

Week 54

52.3 (124/237)

22.9 (25/109)

< 0.001

ADA ever

56.0 (169/302)

34.4 (44/128)

< 0.001

1a: Comparison of ADA development in patients treated with CT-P13 

Category

INF RA (n=300)

INF AS (n=122)

p value

screening

2.0 (6/298)

0.8 (1/120)

0.46

Week 14

25.8 (70/271)

11.0 (13/118)

0.001

Week 30

48.2 (122/253)

22.5 (25/111)

< 0.001

Week 54

49.5 (108/218)

26.7 (28/105)

< 0.001

ADA ever

54.7 (164/299)

32.0 (39/122)

< 0.001

1b: Comparison of ADA development in patients treated with INF 


Disclosure:

J. Braun,
None;

X. Baraliakos,
None;

A. Kudrin,
None;

H. Kim,

Celltrion,

3;

S. J. Lee,

CELLTRION, Inc.,

3.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/striking-discrepancy-in-the-development-of-anti-drug-antibodies-ada-in-patients-with-rheumatoid-arthritis-ra-and-ankylosing-spondylitis-as-in-response-to-infliximab-inf-and-its-biosimilar-ct-p/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences